centene executive team centene executive team

CENTENE IS COMMITTED TO CORPORATE SUSTAINABILITY . You will be able to work 100% remote or hybrid in this summer intern position. A free inside look at Centene salary trends based on 8393 salaries wages for 2135 jobs at Centene. As Centenes CFO, He is responsible for managing the accounting, treasury, capital markets, tax, actuarial services, health economics, financial planning, investor relations, and procurement departments. Sarah London is the Chief Executive Officer of Centene Corporation, a diversified healthcare enterprise providing a portfolio of government-sponsored healthcare programs focusing on under-insured and uninsured individuals to more than 26 million Americans. Centene announced changes to its executive leadership team Dec. 14 as President and COO Brent Layton takes on an advisory role as he "transitions toward retirement.". Drew Asher has worked as the chief financial officer (CFO) and chief accounting officer since May 2021. Drew Asher, CFO. Fasola, who had run Magellan Health before Centene bought the company earlier this year, replaces Brent Layton who joined Centene in 2006 and will become Senior Advisor to the CEO, as he begins his transition towards retirement, Centenes statement said. Sarah London, Chief Executive Officer. How experienced are the management team and are they aligned to shareholders interests? You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). Centeneuses its investor relations website to publish important information about the company, including information that may be deemed material to investors. Conditions. Centene is in My Favorite - Delete. With its most recent Medicaid contract win in Delaware, Centene now has business in 30 states. Before Centene, Brinn worked as a bookkeeper at a hospital. In addition, she recently became Centene Corporations chief executive officer. Without limiting the foregoing, forward-looking statements often use words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "seek," "target," "goal," "may," "will," "would," "could," "should," "can," "continue" and other similar words or expressions (and the negative thereof). Other executives include Drew Asher, Chief Financial Officer; Jim Murray, Chief Operating Officer and 17 others. Brian LeClaire, CIO. The company and Mr. Schwaneke "mutually agreed" that he would resign from his . News Jan 23, 2023. Business Journals Centene completes sale of benefit management subsidiary to Evolent Health. Her focus has been advancing integrated, value-based care models through the development and application of data-driven insights and technology. Centene is an equal opportunity employer that is committed to diversity, and values the ways in which we are different. We have a unique opportunity to empower our members, providers, and their communities in this transformation. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including, but not limited to: the impact of COVID-19 on global markets, economic conditions, the healthcare industry and our results of operations and the response by governments and other third parties; the risk that regulatory or other approvals required for the Magellan Acquisition may be delayed or not obtained or are obtained subject to conditions that are not anticipated that could require the exertion of management's time and our resources or otherwise have an adverse effect on us; the risk that Magellan Health's stockholders do not approve the definitive merger agreement; the possibility that certain conditions to the consummation of the Magellan Acquisition will not be satisfied or completed on a timely basis and accordingly the Magellan Acquisition may not be consummated on a timely basis or at all; uncertainty as to the expected financial performance of the combined company following completion of the Magellan Acquisition; the possibility that the expected synergies and value creation from the Magellan Acquisition or the WellCare Acquisition will not be realized, or will not be realized within the applicable expected time periods; the exertion of management's time and our resources, and other expenses incurred and business changes required, in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for the Magellan Acquisition; the risk that unexpected costs will be incurred in connection with the completion and/or integration of the Magellan Acquisition or that the integration of Magellan Health will be more difficult or time consuming than expected; the risk that potential litigation in connection with the Magellan Acquisition may affect the timing or occurrence of the Magellan Acquisition or result in significant costs of defense, indemnification and liability; a downgrade of the credit rating of our indebtedness, which could give rise to an obligation to redeem existing indebtedness; the possibility that competing offers will be made to acquire Magellan Health; the inability to retain key personnel; disruption from the announcement, pendency and/or completion and/or integration of the Magellan Acquisition or the integration of the WellCare Acquisition, or similar risks from other acquisitions we may announce or complete from time to time, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships; our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical utilization rates due to the impact of COVID-19; competition; membership and revenue declines or unexpected trends; changes in healthcare practices, new technologies, and advances in medicine; increased healthcare costs; changes in economic, political or market conditions; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act (ACA) and the Health Care and Education Affordability Reconciliation Act, collectively referred to as the ACA and any regulations enacted thereunder that may result from changing political conditions, the new administration or judicial actions, including the ultimate outcome in "Texas v. United States of America" regarding the constitutionality of the ACA; rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting our government businesses; our ability to adequately price products; tax matters; disasters or major epidemics; changes in expected contract start dates; provider, state, federal, foreign and other contract changes and timing of regulatory approval of contracts; the expiration, suspension, or termination of our contracts with federal or state governments (including, but not limited to, Medicaid, Medicare, TRICARE or other customers); the difficulty of predicting the timing or outcome of pending or future legal and regulatory proceedings or government investigations; challenges to our contract awards; cyber-attacks or other privacy or data security incidents; the possibility that the expected synergies and value creation from acquired businesses, including businesses we may acquire in the future, will not be realized, or will not be realized within the expected time period; the exertion of management's time and our resources, and other expenses incurred and business changes required in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for acquisitions; disruption caused by significant completed and pending acquisitions making it more difficult to maintain business and operational relationships; the risk that unexpected costs will be incurred in connection with the completion and/or integration of acquisition transactions; changes in expected closing dates, estimated purchase price and accretion for acquisitions; the risk that acquired businesses will not be integrated successfully; restrictions and limitations in connection with our indebtedness; our ability to maintain or achieve improvement in the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; availability of debt and equity financing, on terms that are favorable to us; inflation; foreign currency fluctuations; and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission. She participates in Audit, Compensation, and Technology Committees. Learn about Centene Corporation (CNC) stock's management team. Centene said in a statement released Wednesday. CENTENE CORP annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Ms. London was part of the team that launched Accretive Health's Quality & Total . She is responsible for overseeing Centene's day-to-day . "With these appointments, Centene is aligning the outstanding talent within our senior executive team with the Company's value creation mission and long-term strategy for growth," London said. CENTENE APPOINTS SARAH LONDON AS CHIEF EXECUTIVE OFFICER. ", Drew Asher, Centene's Chief Financial Officer, said, "Sarah brings a modern vision to the helm of one of this country's most important healthcare companies. Our Managed Care segment provides health plan coverage to individuals through government-subsidized and commercial programs. The premier source of breaking business news for the government contracting industry, GovCon Wire provides informative, to-the-point stories of the most significant contract awards, top-level executive moves, M&A activities and financial results of the sectors most notable players. Position Purpose: Centene.com uses cookies. Prior to Optum Ventures, Ms. London served as Chief Product Officer for Optum Analytics, the business unit responsible for driving strategy and commercialization of Optum's integrated data and analytics solutions into the provider, payer and life sciences markets.